Search Result

Results for "

RNA-dependent RNA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (39) Antibiotic (12) Apoptosis (7) Autophagy (3) Bacterial (17) Cytochrome P450 (1) Dengue virus (1) Drug Metabolite (2) Endogenous Metabolite (1) ERK (1) Filovirus (2) Flavivirus (1) Fungal (4) HCV (19) HCV Protease (4) HIV (1) Influenza Virus (20) Isotope-Labeled Compounds (4) JNK (1) Keap1-Nrf2 (1) mTOR (2) Parasite (5) Phosphatase (3) Reverse Transcriptase (3) RSV (3) SARS-CoV (20) Sirtuin (3) Topoisomerase (3)
By Research Areas:	Cancer (17) Cardiovascular Disease (3) Infection (71) Inflammation/Immunology (3) Neurological Disease (2)
Click Chemistry:	Azide (3)
Oligonucleotides:	Nucleosides and their Analogs (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: DNA/RNA Synthesis Small Interfering RNA (siRNA) Apical Sodium-Dependent Bile Acid Transporter CaMK CDK SNIPERs DNA-PK VDAC SGLT PDK-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10241

Simeprevir Maximum Cited Publications 40 Publications Verification TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-19643

JTK-109	HCV Protease	Infection
JTK-109 is a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase. JTK-109 has NS5B inhibitory activity with IC₅₀ value of 0.017μM. JTK-109 can be used for the research of hepatitis C virus (HCV) .

HY-155110

Antiviral agent 34	Influenza Virus	Infection
Antiviral agent 34 is a potent and orally active antiviral agent against influenza A and B subtypes with an EC₅₀ value of 0.8 nM for H1N1 proliferation. Antiviral agent 34 derivatives inhibited influenza virus proliferation by targeting influenza virus RNA-dependent RNA polymerase. Antiviral agent 34 can be used for influenza virus research .

HY-151254

CYP2C19-IN-1	Cytochrome P450 Influenza Virus DNA/RNA Synthesis	Infection
CYP2C19-IN-1 (compound 20d) is a potent CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a K_i value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-16750

Radalbuvir GS-9669	HCV	Infection
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM) .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-115929

DENV-IN-4	DNA/RNA Synthesis	Infection
DENV-IN-4 is a potent DENV inhibitor (DENV EC₅₀=4.79 μM, Vero CC₅₀>100 μM, SI>20.9). DENV-IN-4 can inhibit the expression level of DENV2 with concentration-dependence and reduce RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 has antiviral effect .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-115730

RdRP-IN-3	DNA/RNA Synthesis Influenza Virus	Infection
RdRP-IN-3 is a promising anti-influenza agent candidate by inhibiting the activity of RNA-dependent RNA polymerase (RdRp).

HY-168510

ATV03	Influenza Virus	Infection
ATV03 is an anti-influenza virus agent with excellent anti-influenza A and B virus activity. ATV03 inhibits anti-influenza A (H3N2) and anti-influenza B with EC₅₀ values of 0.78 nM and 2.02 nM, respectively. ATV03 exerts anti-influenza activity by inhibiting polymerase acidic protein (PA) and RNA-dependent RNA polymerase (RdRp), as well as disrupting nuclear protein .

HY-152294

3′-Deoxy-3′-methyluridine	DNA/RNA Synthesis	Infection
3′-Deoxy-3′-methyluridine is a nucleoside derivative, involving in preparation inhibitors of RNA-dependent RNA viral polymerase .

HY-162111

SARS-CoV-2-IN-73	SARS-CoV	Infection
SARS-CoV-2-IN-73 (compound 4) is a *SARS-CoV-2 RNA-dependent* RNA polymerase (RdRp)** blocker .

HY-134909

AS-136A	DNA/RNA Synthesis	Infection
AS-136A is an orally active non-nucleoside inhibitor of the measles virus RNA-dependent RNA polymerase (RdRp) with an IC₅₀ of 2 µM for measles virus .

HY-152239

RdRP-IN-5	Influenza Virus	Infection
RdRP-IN-5 (compound 20) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. RdRP-IN-5 can be used in research of influenza virus .

HY-152239A

cis-RdRP-IN-5	Influenza Virus	Infection
cis-RdRP-IN-5 (compound 19) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. cis-RdRP-IN-5 can be used in research of influenza virus .

HY-152239B

trans-RdRP-IN-5	Influenza Virus	Infection
trans-RdRP-IN-5 (compound 18) is a potent influenza virus RNA-dependent RNA polymerase (RdRP) inhibitor. trans-RdRP-IN-5 can be used in research of influenza virus .

HY-N0637

Eriodictyol 3 Publications Verification Huazhongilexone	Keap1-Nrf2 Influenza Virus DNA/RNA Synthesis Endogenous Metabolite	Infection Inflammation/Immunology
Eriodictyol is a flavonoid isolated from the Chinese herb, with antioxidant and anti-inflammatory activity. Eriodictyol induces Nrf2 signaling pathway. Eriodictyol is also a potent *influenza RNA-dependent* RNA polymerase inhibitor with an IC₅₀** of 18 nM.

HY-14768

Favipiravir Maximum Cited Publications 40 Publications Verification T-705	DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-W011834

2'-O-Methylcytidine	HCV	Infection
2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate .

HY-14768A

Favipiravir sodium T-705 sodium	DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (T-705) sodium is an inhibitor of viral RNA polymerase (RNA polymerase), which is converted into its active form Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the activity of influenza virus RNA-dependent RNA polymerase (RdRP) with an IC₅₀ of 341 nM .

HY-162793

RdRP-IN-8	Influenza Virus	Infection
RdRP-IN-8 (compound 45) is an anti-influenza virus compound. RdRP-IN-8 inhibits viral RNA-dependent RNA polymerase (RdRP) activity by disrupting heterodimerization of PA and PB1 subunits (EC₅₀=0.13 μM) .

HY-12429

Beclabuvir 3 Publications Verification BMS-791325	HCV	Infection
Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM .

HY-13977A

PKR-IN-C16 5 Publications Verification	Apoptosis	Neurological Disease
PKR-IN-C16 (Compound C16) is a specific *double-stranded RNA-dependent* protein kinase (PKR**) inhibitor. PKR-IN-C16 shows promising neuroprotective properties and can rescue acute brain lesions .

HY-N0112

Dihydromyricetin 10+ Cited Publications Ampelopsin; Ampeloptin	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent *influenza RNA-dependent* RNA polymerase inhibitor with an IC₅₀** of 22 μM.

HY-126303

GS-443902 GS-441524 triphosphate; Remdesivir metabolite	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .

HY-154990

RdRP-IN-7	SARS-CoV	Infection
RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC₅₀ of 8.2 μM, an IC₉₀ of 14.1 μM and an CC₉₀ of 79.1 μM. RdRP-IN-7 can be used for antiviral research .

HY-156291

XSJ2-46	Influenza Virus	Infection
XSJ2-46, 5'-amino NI analog, is an antiviral agent. XSJ2-46 has anti-Zika virus activity. XSJ2-46 exhibits reasonable inhibition of RNA-dependent RNA polymerases (RdRp) with an IC₅₀ value of 8.78 μM .

HY-12429A

Beclabuvir hydrochloride BMS-791325 hydrochloride	HCV	Infection
Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM .

HY-112464

PKR Inhibitor, negative control	Others	Neurological Disease
PKR Inhibitor, negative control is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitor, which can be used as a negative control. PKR Inhibitor, negative control can also inhibit LK-induced neuronal death, exhibiting significant neuroprotective effects .

HY-14768R

Favipiravir (Standard)	DNA/RNA Synthesis Influenza Virus SARS-CoV Bacterial	Infection
Favipiravir (Standard) is the analytical standard of Favipiravir. This product is intended for research and analytical applications. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-126303C

GS-443902 trisodium 5+ Cited Publications GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-163147

PAN endonuclease-IN-1	Influenza Virus	Infection
PAN endonuclease-IN-1 (Compound 23) is a potent PAN endonuclease inhibitor, with K_d values of 277 μM, 384 μM and 328 μM for WT, I38T and E23K PA_N endonucleases, respectively. The RNA-dependent RNA polymerase acidic N-terminal (PAN) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target .

HY-W011834S

2'-O-Methylcytidine-d3	Isotope-Labeled Compounds HCV	Infection
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

HY-W769714

Favipiravir-13C3 T-705-¹³C₃	Isotope-Labeled Compounds Antibiotic Bacterial	Infection
Favipiravir- ¹³C3 is the ¹³C labeled isotope of Favipiravir- ¹³C3(HY-14768 ).Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-N0112R

Dihydromyricetin (Standard)	mTOR Influenza Virus DNA/RNA Synthesis Autophagy	Infection Cancer
Dihydromyricetin (Standard) is the analytical standard of Dihydromyricetin. This product is intended for research and analytical applications. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-109072

Riamilovir	SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2 .

HY-18649

Galidesivir hydrochloride 5+ Cited Publications BCX4430 hydrochloride; Immucillin-A hydrochloride	DNA/RNA Synthesis SARS-CoV Filovirus	Infection
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC₅₀s ranging from ~3 to ~68 μM .

HY-18649A

Galidesivir 5+ Cited Publications BCX4430; Immucillin-A	DNA/RNA Synthesis SARS-CoV Filovirus	Infection
Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC₅₀s ranging from ~3 to ~68 μM .

HY-10118

Filibuvir 2 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the *HCV nonstructural 5B protein (NS5B) RNA-dependent* RNA polymerase (RdRp)*. Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA* synthesis and potently decreases viral RNA accumulation .

HY-118032

Bozepinib	Apoptosis Autophagy JNK ERK	Cancer
Bozepinib is a PKR (RNA-dependent protein kinase) activator and potently inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces PKR-mediated apoptosis and synergizes with IFNα to trigger apoptosis, autophagy and senescence. Bozepinib also demonstrates in vivo antitumor and antimetastatic efficacy in xenografted nude mice .

HY-147903

HIV-1 inhibitor-42	HIV	Infection
HIV-1 inhibitor-42 (compound 5b) is a potent HIV-1 inhibitor, with an IC₅₀ of 0.06 μM. HIV-1 inhibitor-42 inhibits HIV-1 RT RNA-dependent DNA polymerase and DNA-dependent DNA polymerase, with IC₅₀ values of 0.518 and 0.072 μM .

HY-13998R

Dasabuvir (Standard)	HCV DNA/RNA Synthesis	Infection
Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-N0540

Cynaroside 5+ Cited Publications Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside	Influenza Virus DNA/RNA Synthesis Apoptosis Parasite Bacterial Fungal	Infection Cancer
Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 32 nM. Cynaroside also is a promising inhibitor for H₂O₂-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities .

HY-B0220F

Erythromycin (glutamate)	Bacterial Antibiotic DNA/RNA Synthesis	Infection Cancer
Erythromycin glutamate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin glutamate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid ^[1][2]. Erythromycin glutamate also exhibits antitumor and neuroprotective effect in different fields of research ^[3][4].

HY-162719

RH12	SARS-CoV	Infection
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC₅₀ is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC₅₀ is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC₅₀ of 17.5 nM .

HY-B0220S2

Erythromycin-d3	Bacterial DNA/RNA Synthesis Antibiotic	Infection
Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626	HCV DNA/RNA Synthesis	Infection
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-B0914A

10-Undecenoic acid zinc salt 1 Publications Verification Zinc undecylenate	Fungal DNA/RNA Synthesis	Infection
10-Undecenoic acid zinc salt is a RNA-dependent RNA polymerase (RdRp) inhibitor, with an IC₅₀ of 1.13, 21.33 and 1.79 μM for WT-RdRp, D535ARdRp and D692A-RdRp, respectively. 10-Undecenoic acid zinc salt reduces infectious virus yield in Huh7 cells with an EC₅₀ of 7.43 μM. 10-Undecenoic acid zinc salt has anti-infective and anti-fungal activity. 10-Undecenoic acid zinc salt can be used for the research of Zika virus (ZIKV) .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library

311 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 311 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

HY-L044

Nucleotide Compound Library

539 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 539 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Species:	Virus (1) Human (1)
Tag:	His (2)
Source:	Sf9 insect cells (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74579

	SARS-CoV-2 RDRP Protein (sf9, His) SARS-CoV-2 (2019-nCoV) RNA-dependent RNA polymerase/RDRP Protein	Virus	Sf9 insect cells
	The function of viral RNA transcription and replication is performed by a specific RNA dependent RNA polymerase (RdRp) region present in ORF1ab, including non-structure proteins NSP12 with nucleotidyltransferase activity and NSP13 with a Zinc-binding domain involved in replication and transcription. The catalytic subunit (Nsp12) RdRp enzyme is the core component of multisubunit replication and transcription complex of NSPs. SARS-CoV-2 RDRP Protein (sf9, His) is the recombinant Virus-derived SARS-CoV-2 RDRP protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of SARS-CoV-2 RDRP Protein (sf9, His) is 932 a.a., with molecular weight of ~91.3 kDa.

HY-P700582

	EIF2AK2 Protein, Human (P. pastoris, His) eukaryotic translation initiation factor 2-alpha kinase 2; PRKR, protein kinase, interferon inducible double stranded RNA dependent; interferon-induced, double-stranded RNA-activated protein kinase; EIF2AK1; PKR; p68 kinase; eIF-2A protein kinase 2; P1/eIF-2A protein kinase; tyrosine-protein kinase EIF2AK2; interferon-inducible elF2alpha kinase; double stranded RNA activated protein kinase; protein kinase, interferon-inducible double stranded RNA dependent; PRKR; MGC126524	Human	P. pastoris
	The EIF2AK2 protein is an interferon-inducing kinase that initiates the innate immune response against viral infection. It phosphorylates eIF-2-α, activating the integrated stress response, inhibiting overall protein synthesis and favoring ISR-specific mRNAs such as ATF4. EIF2AK2 Protein, Human (P. pastoris, His) is the recombinant human-derived EIF2AK2 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of EIF2AK2 Protein, Human (P. pastoris, His) is 550 a.a., with molecular weight of 64 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-W011834S

2'-O-Methylcytidine-d3
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

HY-W769714

Favipiravir-13C3
Favipiravir- ¹³C3 is the ¹³C labeled isotope of Favipiravir- ¹³C3(HY-14768 ).Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

HY-B0220S2

Erythromycin-d3

Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].

HY-B0220S

Erythromycin-d6

Erythromycin-d₆ is the deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].

HY-B0220S1

Erythromycin-13C,d3

Erythromycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81299A

	Phospho-PKR (Thr446) Antibody (YA1026) EIF2AK2; PKR; PRKR; Interferon-induced; double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2; eIF-2A protein kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein k	WB, IHC-P, IP, ChIP	Human
	Phospho-PKR (Thr446) Antibody (YA1026) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1026), targeting Phospho-PKR (Thr446), with a predicted molecular weight of 62 kDa (observed band size: 62 kDa). Phospho-PKR (Thr446) Antibody (YA1026) can be used for WB, IHC-P, IP, ChIP experiment in human background.

HY-P81299

	Phospho-PKR (Thr451) Antibody (YA1025) EIF2AK2; PKR; PRKR; Interferon-induced; double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2; eIF-2A protein kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein k	WB	Human
	Phospho-PKR (Thr451) Antibody (YA1025) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-PKR (Thr451), with a predicted molecular weight of 62 kDa (observed band size: 74 kDa). Phospho-PKR (Thr451) Antibody (YA1025) can be used for WB experiment in human background.